Quick Answer
Carnosine Fatigue Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: The Cochrane Risk of Bias (ROB) 2.0 tool was used to assess the ROB in randomized controlled trials (RCTs).
Key Takeaways
- 01The Cochrane Risk of Bias (ROB) 2.0 tool was used to assess the ROB in randomized controlled trials (RCTs). [Hsiao YF (2026)]
- 02Additionally, meta-analysis results showed that L-carnosine combined with anserine or antioxidant supplementation significantly improved the MMSE score compared to placebo (pooled net change = 0.62; 95% CI 0.23, 1.01), with small statistical heterogeneity ( I 2 = 21.3%). [Hsiao YF (2026)]
- 03Conclusions: A low strength of evidence suggests that L-carnosine supplement combined with anserine or antioxidants can slow cognitive function decline among healthy elderly or patients with probable Alzheimer's Disease or mild neurocognitive disorder. [Hsiao YF (2026)]
- 04Introduction: Previous research has shown that L-carnosine (β-alanyl-L-histidine) can reduce cognitive decline and improve mental health outcomes, but an updated systematic review of the effects of carnosine alone or in combination with other supplemental nutrients or bioactive compounds on these interconnected outcomes is lacking. [Hsiao YF (2026)]
The current Migaku evidence database contains 2 reusable source documents for Carnosine Fatigue Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts.
- The Cochrane Risk of Bias (ROB) 2.0 tool was used to assess the ROB in randomized controlled trials (RCTs). [Hsiao YF (2026); evidence level 1]
- Additionally, meta-analysis results showed that L-carnosine combined with anserine or antioxidant supplementation significantly improved the MMSE score compared to placebo (pooled net change = 0.62; 95% CI 0.23, 1.01), with small statistical heterogeneity ( I 2 = 21.3%). [Hsiao YF (2026); evidence level 1]
- Conclusions: A low strength of evidence suggests that L-carnosine supplement combined with anserine or antioxidants can slow cognitive function decline among healthy elderly or patients with probable Alzheimer's Disease or mild neurocognitive disorder. [Hsiao YF (2026); evidence level 1]
- Introduction: Previous research has shown that L-carnosine (β-alanyl-L-histidine) can reduce cognitive decline and improve mental health outcomes, but an updated systematic review of the effects of carnosine alone or in combination with other supplemental nutrients or bioactive compounds on these interconnected outcomes is lacking. [Hsiao YF (2026); evidence level 1]
- 1 1 2 3 4 5 6 7 8 9–14 Carnosine (β-alanine-L-histidine) and its biochemically modified derivatives comprise a family of histidyl-containing dipeptides found in abundance in highly metabolic tissues (skeletal muscle, heart, brain) of all species []. [O'Toole Timothy E. (2026); evidence level 2]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources